The Toxicology Drug Screening Market was valued at USD 5,848 million in 2020, and it is expected to reach USD 9,705 million by 2026, registering a CAGR of 8.30% during the forecast period.
Owing to the current COVID-19 situation and the urge to develop a vaccine and an effective treatment, toxicological screening methods have been extensively used in drug development by various research laboratories and biopharmaceutical industries. According to an article published by the Science Advisory Board in July 2020, researchers are using a strain of SARS-CoV-2 that can infect mice to produce a new mouse model of infection to facilitate several in vivo testing of COVID-19 vaccine candidates and therapies. However, there is a significant decline in the non-COVID-19 related research which is going to affect the growth.
In vitro, in vivo, and in-silico are the different techniques that are used to assess drug toxicity and to confirm the safety of the drug in the drug discovery and drug development process of clinical and pre-clinical trials. Toxicity testing has become proficient with various advanced technologies aiding the process and it is currently anticipated to take advantage of promising revolutions from the field of biotechnology and pharmaceuticals.
The studied market growth is driven by three major factors such as increasing research and development expenditure, technological advancements in toxicity screening, and rising demand for toxicological drug screening. As per the annual report of the companies in 2019, Roche incurred the research and development (R&D) expense of CHF 11.7 billion, whereas Jhonson and Johnson invested USD 11.36 billion in R&D. Also, the recent technological developments by the market players and researchers are contributing to the growth of the market studied. For instance, in the research study published in Biofabrication, 2020, a primary human cell- and stem cell-derived 3D organoid technology was employed to screen a panel of drugs that were recalled from the market by the FDA. The platform comprised of multiple tissue organoid types that remain viable for at least 28 days in vitro. Earlier in August 2019, Covance launched a laboratory solution within its functional service provider (FSPx) offering, which expanded its clinical analytics service and clinical operations capabilities.
The rising prevalence of various diseases is also one of the major reasons fuelling the market demand for various toxicological screening procedures by increasing the focus of the market players for developing new therapeutics. As per the World Health Organization (WHO), the burden of chronic diseases is increasing. This is expected to increase the demand for the development of new drugs and which is going to further raise the demand for clinical trials. It has been observed that almost half of the total chronic disease deaths are attributable to cardiovascular diseases, obesity, and diabetes which are showing increasing trends. The WHO 2018 Report stated that chronic disease kills 41 million people every year, which is equivalent to 71% of all deaths globally.
Also, cancer is the second leading cause of death globally, and it is responsible for an estimated 9.6 million deaths in 2018, as per the WHO report. Globally, about 1 in 6 deaths is due to cancer. In addition, approximately 70% of deaths from cancer occur in low- and middle-income countries. The Cancer Research UK also suggests that if recent trends in incidence of major cancers and population growth are consistent, it is predicted that there will be 27.5 million new cancer cases worldwide, each year, by 2040. This estimate is an increase of 61.7% from 2018, as per the organization's report in 2019. Thus, the rising burden of these diseases is expected to fuel market growth.
Applications of toxicity testing are set to increase with advances in biotechnology, pharmaceuticals resulting in a demand for the same in the market. A number of emerging fields and techniques are contributing major new insights for understanding biological responses to chemicals in human tissues. There is an increase in worldwide pharmaceutical research and development spending when compared to 2016, global research and development spending in 2017 surged by 3.9% to 165 USD billion, and average research and development spending moderately increased to 20.9%. Increasing research and development activities, technological advancements in toxicology drug screening, and a rise in demand for toxicology drug screening in the pharmaceutical and biotechnology industries are the key driving factors for the market growth. However, the longer time duration of the sample testing and stringent regulation by the government on toxicological testing of the human drug molecule is expected to hinder market growth over the forecast period.
Key Market Trends
In-silico Segment is Expected to register Robust Growth in the Toxicology Drug Screening Market
The in-silico segment holds a significant market share in the toxicology drug screening market and is anticipated to show robust growth over the forecast period. In silico methods helps in identifying drug targets via bioinformatics tools and also used to analyze the target structures for generating candidate molecules, possible binding/ active sites, check for their drug-likeness, and further optimize the molecules to improve binding characteristics.
As per 2019 estimates of Food Drug and Administration (FDA) the pipeline drugs amounted for the growth rates of 6% as compared to the growth rate of previous year 2.7%. Currently, the drug discovery process is revolunizing with the deployment of various proteomics, genomics, bioinformatics, and efficient technologies like in silico ADMET screening and structure-based drug design, virtual screening, de novo design, etc help in the detection of drug toxicology.
Increasing research and development activities, technological advancements in drug screening and a rise in demand for toxicology drug screening in the pharmaceutical and biotechnology industries are the key driving factors in the in-silico segment.
In-silico platform is considered as potential tool in various COVID-19 related research in predicting immune responses of potential candidate vaccines. The Universal Immune System Simulator (UISS) in silico platform has an strong potential to predict the outcome of vaccination strategy against COVID-19 virus, and has been frequently employed in various researches to speed-up and drive the discovery pipeline of vaccine. Hence, the segment is expected to show positive growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market
North America is expected to hold a major market share in the global toxicology drug screening market due to growing research and development activities to detect toxicity levels in the human body at early stages in this region. The research and development in this region reached a plateau, as these trials are being outsourced to other regions, like the Asian market. However, increasing R&D investments and increasing demand for drug development are the major factors driving the market growth. In this region, pharmaceutical companies spend more money, time, and energy on R&D than most of the other pharmaceutical companies in another region. According to the National Institute of Health data, in the fiscal year 2017, clinical research funding by the NIH was around USD 12.7 billion U.S. dollars and it was further increased to USD 15 billion in 2019.
Also, the R&D budgets of the pharmaceutical companies have also increased in the past few years, owing to the rising burden of diseases, complex molecules, and therapy segments. According to the data from Pharmaceutical Research and Manufacturers of America 2019, Research and development expenditure: U.S. pharmaceutical industry has increased from 15.2 billion in 1995 to 79.6 billion in 2018.
Moreover, due to the presence of the key market players and focused R&D of new drugs, the market for clinical trials in the United States has been rising gradually which is also impacting the toxicology drug screening market positively in the region. According to The Biotechnology Innovation Organization, in 2019, around 50 novel drugs were approved by the Center for Drug Evaluation and Research (CDER). On the other hand, in over 20 novels, drugs were introduced in 2016. Furthermore, technical advancements and supportive government regulations have led to the rapid development of innovative and cost-effective testing and the presence of well-established healthcare infrastructure is also fueling the growth of the overall market to a large extent.
The Toxicology Drug Screening Market is consolidated and moderately competitive with the presence of few key players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Abbott Laboratories, Agilent Technologies, Inc, Covance, Inc, Bio-Rad Laboratories, Inc, Eurofins Scientific, GE Healthcare, BioReliance, Inc, Thermo Fisher Scientific, Inc, Quest Diagnostics, and Enzo Life Sciences, Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Research and Development Activities
- 4.2.2 Technological Advancements in Toxicology Drug Screening
- 4.2.3 Rise in Demand for Toxicology Drug Screening in the Pharmaceutical and Biotechnology industries
- 4.3 Market Restraints
- 4.3.1 Longer Time for Sample Testing
- 4.3.2 Regulatory Issues Regarding Approval of Healthcare Molecule
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Testing Type
- 5.1.1 In vitro
- 5.1.2 In vivo
- 5.1.3 In silico
- 5.2 By Product
- 5.2.1 Instruments
- 5.2.2 Reagents and Consumables
- 5.2.3 Animal Models
- 5.2.4 Softwares
- 5.2.5 Others
- 5.3 By Application
- 5.3.1 Immunotoxicity
- 5.3.2 Systemictoxicity
- 5.3.3 Developmental and Reproductive Toxicity (DART)
- 5.3.4 Endocrine Disruption
- 5.3.5 Others
- 5.4 Geography
- 5.4.1 North America
- 126.96.36.199 United States (By Testing Type, By Product, and By Application)
- 188.8.131.52 Canada (By Testing Type, By Product, and By Application)
- 184.108.40.206 Mexico (By Testing Type, By Product, and By Application)
- 5.4.2 Europe
- 220.127.116.11 Germany (By Testing Type, By Product, and By Application)
- 18.104.22.168 United Kingdom (By Testing Type, By Product, and By Application)
- 22.214.171.124 France (By Testing Type, By Product, and By Application)
- 126.96.36.199 Italy (By Testing Type, By Product, and By Application)
- 188.8.131.52 Spain (By Testing Type, By Product, and By Application)
- 184.108.40.206 Rest of Europe (By Testing Type, By Product, and By Application)
- 5.4.3 Asia-Pacific
- 220.127.116.11 China (By Testing Type, By Product, and By Application)
- 18.104.22.168 Japan (By Testing Type, By Product, and By Application)
- 22.214.171.124 India (By Testing Type, By Product, and By Application)
- 126.96.36.199 Australia (By Testing Type, By Product, and By Application)
- 188.8.131.52 South Korea (By Testing Type, By Product, and By Application)
- 184.108.40.206 Rest of Asia-Pacific (By Testing Type, By Product, and By Application)
- 5.4.4 Middle East and Africa
- 220.127.116.11 GCC (By Testing Type, By Product, and By Application)
- 18.104.22.168 South Africa (By Testing Type, By Product, and By Application)
- 22.214.171.124 Rest of Middle East and Africa (By Testing Type, By Product, and By Application)
- 5.4.5 South America
- 126.96.36.199 Brazil (By Testing Type, By Product, and By Application)
- 188.8.131.52 Argentina (By Testing Type, By Product, and By Application)
- 184.108.40.206 Rest of South America (By Testing Type, By Product, and By Application)
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 Agilent Technologies, Inc
- 6.1.3 Bio-Rad Laboratories, Inc.
- 6.1.4 BioReliance, Inc. (Sigma-Aldrich)
- 6.1.5 Charles River Laboratories International Inc.
- 6.1.6 Covance, Inc (LabCorp)
- 6.1.7 Enzo Life Sciences, Inc
- 6.1.8 Eurofins Scientific
- 6.1.9 F. Hoffmann-La Roche Ltd
- 6.1.10 GE Healthcare
- 6.1.11 Laboratory Corporation of America Holdings
- 6.1.12 Merck KGaA
- 6.1.13 Promega Corporation
- 6.1.14 Quest Diagnostics
- 6.1.15 The Jackson Laboratory
- 6.1.16 Thermo Fisher Scientific, Inc
- 6.1.17 Wuxi AppTec
7 MARKET OPPORTUNITIES AND FUTURE TRENDS